Eli Lilly shares hurt by breast cancer treatment drug's failure

  • Follow Business

A potential breast cancer treatment in development by Eli Lilly failed to meet its main goal in a late-stage study comparing it to a fake drug. Shares of the drugmaker tumbled 3 percent on the news.

Shares of Eli Lilly tumbled 3 percent.  FILE/ASSOCIATED PRESS
Shares of Eli Lilly tumbled 3 percent.

The Indianapolis company no longer plans to seek regulatory approval for the drug, ramucirumab, in patients with a form of breast cancer that has spread. However, Lilly will seek approval to use the treatment in combination with chemotherapy in stomach cancer patients after it performed better in a separate study on those patients.

Investors had relatively low expectations for the drug in treating breast cancer, Bernstein financial analyst Dr. Tim Anderson said in a research note. He expects the drug to generate about $600 million in annual revenue by 2020 from its use in treating gastric cancer.


Eli Lilly & Co. (LLY)

Thursday’s close:

$51.04 ▼ $1.57, or 2.98%

52-week range $49-$58

Annual dividend $1.96

Dividend yield 3.8%

Price-earnings ratio * 12

Total return YTD 6%

3-year ** 18%

5-year ** 7%

10-year ** 3%

Market $57.5 value billion

Note: Total returns through Thursday; * Trailing 12 months; ** Annualized

Source: FactSet, Associated Press

Top headlines

Fired Augusta parks chief loses suit against city

U.S. District Court Judge J. Randal Hall granted the city's request for summary judgment Tuesday, finding Tom Beck was unable to prove his 2012 firing violated the Fair Labor Standards Act.
Search Augusta jobs